Infections caused by the hepatitis B virus, which attacks the liver, are typically treated with drugs that keep the virus from making ever more copies of itself.
However, because those treatments reduce but don’t eliminate the virus, patients have to take the drugs indefinitely, according to the World Health Organization.
Ionis Pharmaceuticals (NASDAQ: IONS) has a pipeline of two drugs that the biotech says target the root cause of liver disease associated with chronic hepatitis B. (The condition is considered chronic if patients test positive for more than six months). The drugs are designed to reduce the production of viral… Read more »
UNDERWRITERS AND PARTNERS